Dr. Dennis M. Dixon, Chief, Bacteriology and Mycology Branch, Dr. Lanling Zou, Chief of Translational Sciences and Dr. Ping Chen, Director of China Office, Nation Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH) visited TenNor Therapeutics on May 22, 2015. Dr. Zhenkun Ma, Founder and CEO, provided an update on TenNor’s antibacterial R&D program. Guests from NIH expressed great interests in TenNor’s novel dual-action molecule platform and a series of dual-action compounds in its current development pipeline. Dr. Dennis Dixon and Dr. Lanling Zou presented their work titled Antibacterial Resistance: Needs and Opportunities and Resources for the Microbiology & Infectious Diseases Research Community respectively. The parties agreed to further discuss collaborative opportunities in antibacterial area and reached broad consensus in directions for potential collaboration.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com